54 results found.

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large Clinical Trial using GS-9973

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies.
GS-9973

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Burkitt Lym Clinical Trial using CPX-351

Children's Hospital Medical Center, Cincinnati - Recruiting 12 Months to 30 years.
- A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies.
CPX-351

Diffuse Large B-cell Lymphoma, or Follicle Center Lymphoma Clinical Trial using Zevalin (ibritumomab tiuxetan)

Spectrum Pharmaceuticals, Inc - Recruiting 60 years or older.
- A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy.
Zevalin (ibritumomab tiuxetan)

Peripheral T-Cell Lymphoma, or Diffuse Large B-Cell Lymphoma Clinical Trial using Gemcitabine; Dexamethasone; Cisplatin; Romidepsin

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma.
Gemcitabine; Dexamethasone; Cisplatin; Romidepsin

Lymphoma, B-Cell Clinical Trial using rituximab [MabThera/Rituxan]; CHOP

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- A Comparative, Randomized, Parallel-group, Multi-centre, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20 Positive Diffuse Large B-cell Lymphoma (DLBCL).
rituximab [MabThera/Rituxan]; CHOP

Lymphoma Clinical Trial using MabThera/Rituxan; Standard chemotherapy

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- A Single Arm, Multicentre, Phase IIIb Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL).
MabThera/Rituxan; Standard chemotherapy

Lymphoma, B-Cell Clinical Trial using RO5072759; rituximab [MabThera/Rituxan]; CHOP chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase III, Multicenter, Open-label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL).
RO5072759; rituximab [MabThera/Rituxan]; CHOP chemotherapy

Lymphoma, B-Cell, Non-Hodgkin's Lymphoma Clinical Trial using rituximab [MabThera/Rituxan]; CHOP; CVP; bendamustine

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- A Randomized, Open-label, Multicenter Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a.
rituximab [MabThera/Rituxan]; CHOP; CVP; bendamustine

Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Mac Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies.
CB-839

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using PCI-32765 (Ibrutinib)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study.
PCI-32765 (Ibrutinib)

Lymphoma, Large B-Cell, Diffuse Clinical Trial using CC-122; CC-223; Rituximab; CC-292

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292 and Rituximab in Diffuse Large B-cell Lymphoma.
CC-122; CC-223; Rituximab; CC-292

Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed F Clinical Trial using Pixantrone + Rituximab; Gemcitabine + Rituximab

Cell Therapeutics - Recruiting 18 years or older.
- A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant.
Pixantrone + Rituximab; Gemcitabine + Rituximab

CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma Clinical Trial using AEB071; Everolimus

Novartis - Recruiting 18 years or older.
- An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma.
AEB071; Everolimus

Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, or High Grade B- Clinical Trial using Rituximab; IT Cytarabine

New York Medical College - Recruiting 3 years to 31 years.
- Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma.
Rituximab; IT Cytarabine

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphob Clinical Trial using Clofarabine; Mitoxantrone

New York Medical College - Recruiting N/A to 30 years.
- A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma.
Clofarabine; Mitoxantrone

Lymphoma, Non Hodgkin Clinical Trial using rituximab [MabThera/Rituxan]

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- OPEN LABEL, SINGLE-ARM, PHASE IIIb CLINICAL TRIAL TO EVALUATE THE SAFETY OF SWITCHING FROM INTRAVENOUS RITUXIMAB TO SUBCUTANEOUS RITUXIMAB DURING FIRST LINE TREATMENT FOR CD20+ NON-HODGKIN'S FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA..
rituximab [MabThera/Rituxan]

Diffuse Large B-Cell Lymphoma Clinical Trial using Bendamustine; Ofatumumab

SCRI Development Innovations, LLC - Recruiting 70 years or older.
- Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy.
Bendamustine; Ofatumumab

Diffuse Large B-Cell Lymphoma Clinical Trial using Rituximab, CMC544, Gemcitabine and Oxaliplatine

The Lymphoma Academic Research Organisation - Recruiting 18 years to 80 years.
- A Multi-center, Phase IB/II, Open Label, Single Arm Study of Inotuzumab Ozogamicin Plus Rituximab (R-CMC544) Alternating With Gemcitabine-oxaliplatin Plus Rituximab(R-GEMOX)in Patients Aged From 18 to 80 Years With CD20 and CD22 Positive Diffuse Large B-cell Lymphoma (DLBCL) in Relapse After/Refractory to 1ST or 2ND Line Treatment, Who Are no Candidates for Autologous Transplant..
Rituximab, CMC544, Gemcitabine and Oxaliplatine

Lymphoma, B-Cell Clinical Trial using inotuzumab ozogamicin

Pfizer - Recruiting 18 years or older.
- A Phase 1/2 Study Of CMC-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-Cell Non-Hodgkin's Lymphoma.
inotuzumab ozogamicin

Diffuse Large B-Cell Lymphoma Clinical Trial using Gemcitabine; Methylprednisolone; Rituximab; Cisplatin; Lenalidomide

Royal Marsden NHS Foundation Trust - Recruiting 18 years or older.
- A Randomised Phase II Study Comparing LEnalidomide Plus Rituximab, GEmcitabine and Methylprednisolone (LR-GEM) to Rituximab, Gemcitabine, Methylprednisolone and cisplatiN (R-GEM-P) in Second-line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)..
Gemcitabine; Methylprednisolone; Rituximab; Cisplatin; Lenalidomide

Recurrent Adult Diffuse Large Cell Lymphoma Clinical Trial using selumetinib; diagnostic laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Single-Arm Phase II Clinical Trial With the Novel MEK Inhibitor AZD-6244 for the Treatment of MCT-1 Related Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
selumetinib; diagnostic laboratory biomarker analysis

B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Diffuse Clinical Trial using rituximab; prednisone; etoposide; doxorubicin hydrochloride; cytarabine; vincristine sulfate; cyclophosphamide; methotrexate; methylprednisolone; leucovorin calcium; therapeutic hydrocortisone

Children's Oncology Group - Recruiting N/A to 18 years.
- Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients.
rituximab; prednisone; etoposide; doxorubicin hydrochloride; cytarabine; vincristine sulfate; cyclophosphamide; methotrexate; methylprednisolone; leucovorin calcium; therapeutic hydrocortisone

Diffuse, Large B-Cell, Lymphoma Clinical Trial using Bortezomib; Rituximab; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine

Grupo Espa¤ol de Linfomas y Transplante Aut¢logo de M‚dula Osea - Recruiting 18 years to 70 years.
- Multicenter Randomized Phase II Study of Treatment With R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI..
Bortezomib; Rituximab; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine

Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chroni Clinical Trial using BMS-936564 (Anti-CXCR4)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies.
BMS-936564 (Anti-CXCR4)

Diffuse Large B-cell Lymphoma Clinical Trial using Blinatumomab

Amgen Research (Munich) GmbH - Recruiting 18 years or older.
- An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE) Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).
Blinatumomab

GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia Clinical Trial using milatuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies.
milatuzumab

Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Diffuse Clinical Trial using doxorubicin hydrochloride; vincristine sulfate; vorinostat; prednisone; rituximab; cyclophosphamide; etoposide; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma.
doxorubicin hydrochloride; vincristine sulfate; vorinostat; prednisone; rituximab; cyclophosphamide; etoposide; laboratory biomarker analysis; pharmacological study

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of the Aurora Kinase A Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies.
alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

Diffuse Large B Cell Lymphoma Clinical Trial using LBH589; Rituximab

Jewish General Hospital - Recruiting 18 years or older.
- A Randomized Phase II Study of Oral Panobinostat (LBH589) With or Without Rituximab to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma.
LBH589; Rituximab

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymph Clinical Trial using bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years to 70 years.
- A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.
bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Diffuse Large Cell Lymphoma Relapsed/Refractory Clinical Trial using Ofatumumab; Etoposide; Cytarabine

University of California, San Francisco - Recruiting 18 years or older.
- A Phase II Study of Intensive Consolidation and Stem Cell Mobilization Therapy With Ofatumumab, Etoposide, and High-dose Ara-C (OVA), Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Ofatumumab; Etoposide; Cytarabine

Lymphoma Clinical Trial using Ibrutinib; Placebo; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone (or equivalent)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma.
Ibrutinib; Placebo; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone (or equivalent)

Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontigu Clinical Trial using lenalidomide; rituximab; cyclophosphamide; doxorubicin hydrochloride; vincristine sulfate; prednisone; laboratory biomarker analysis; positron emission tomography

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.
lenalidomide; rituximab; cyclophosphamide; doxorubicin hydrochloride; vincristine sulfate; prednisone; laboratory biomarker analysis; positron emission tomography

Diffuse Large B Cell Lymphoma Clinical Trial using E7438

Eisai Inc. - Recruiting 18 years or older.
- An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas.
E7438

Non Hodgkin's Lymphoma, NHL, Aggressive NHL, or Diffuse Large B-c Clinical Trial using Veltuzumab and 90Y-Epratuzumab Tetraxetan; 90Y-epratuzumab tetraxetan; veltuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- Phase I/II Study of Veltuzumab Combined With 90Y-Epratuzumab Tetraxetan in Patients With Relapsed/Refractory, Aggressive Non- Hodgkin's Lymphoma.
Veltuzumab and 90Y-Epratuzumab Tetraxetan; 90Y-epratuzumab tetraxetan; veltuzumab

Hodgkin Lymphoma, or Diffuse Large B-Cell Lymphoma Clinical Trial using Cylcophosphamide; Etoposide; Alemtuzumab; Doxorubicin; Prednisone; Filgrastim; Rituximab; Vincristine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas.
Cylcophosphamide; Etoposide; Alemtuzumab; Doxorubicin; Prednisone; Filgrastim; Rituximab; Vincristine

CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30 Pos Clinical Trial using brentuximab vedotin

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas.
brentuximab vedotin

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using anti-endosialin/TEM1 monoclonal antibody MORAb-004; pharmacological study; laboratory biomarker analysis

Morphotek - Recruiting 13 Months to 21 years.
- Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors.
anti-endosialin/TEM1 monoclonal antibody MORAb-004; pharmacological study; laboratory biomarker analysis

Non-Hodgkin's Lymphoma Clinical Trial using ibritumomab tiuxetan; BEAM chemotherapy and autologous stem-cell transplantation

Sheba Medical Center - Recruiting 18 years to 70 years.
- SPINOZA / ???????. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma.
ibritumomab tiuxetan; BEAM chemotherapy and autologous stem-cell transplantation

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 75 years.
- Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV.
leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Diffuse Large B-Cell Lymphoma Clinical Trial using AEB071

Novartis - Recruiting 18 years or older.
- An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma.
AEB071

Lymphoma Clinical Trial using Rituximab; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine; RNA-based gene array studies; Real time PCR gene expression studies; Tissue-array immunohistochemical studies; Immunoglobulin G Fc receptor genotypes determination

University of Miami Sylvester Comprehensive Cancer Center - Recruiting 18 years or older.
- Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP.
Rituximab; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine; RNA-based gene array studies; Real time PCR gene expression studies; Tissue-array immunohistochemical studies; Immunoglobulin G Fc receptor genotypes determination

Diffuse Large Cell B-lymphoma Clinical Trial using PCI-32765

Pharmacyclics - Recruiting 18 years or older.
- A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL).
PCI-32765

Advanced Malignancies, Carcinoma, Non-Small-Cell Lung, Anaplastic Clinical Trial using AP26113

Ariad Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113.
AP26113

Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multipl Clinical Trial using SNS01-T

Senesco Technologies, Inc. - Recruiting 18 years or older.
- Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma.
SNS01-T

Diffuse Large B Cell Lymphoma, or Grade IIIB Follicular Lymphoma Clinical Trial using anthropometric measurement

Centre Henri Becquerel - Recruiting 70 years or older.
- Multicentric Prospective Study to Assess the Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma.
anthropometric measurement

Lymphoma Clinical Trial using Lenalidomide; Rituximab

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma.
Lenalidomide; Rituximab

Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Fo Clinical Trial using PI3K inhibitor BKM120; laboratory biomarker analysis

Mayo Clinic - Recruiting 18 years or older.
- A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma.
PI3K inhibitor BKM120; laboratory biomarker analysis

Burkitt's Lymphoma, or High-grade B-cell Lymphoma Clinical Trial using No intervention (observational study)

Gachon University Gil Medical Center - Recruiting 20 years or older.
- Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL.
No intervention (observational study)

Lymphoma, Lymphoma, Non-Hodgkin, or Large B Cell Diffuse Lymphoma Clinical Trial using FLT-PET/CT; FDG-PET/CT; FLT

Stanford University - Recruiting N/A or older.
- FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma.
FLT-PET/CT; FDG-PET/CT; FLT

Diffuse Large B Cell Lymphoma Clinical Trial using rituximab; cyclophosphamide; vincristine; doxorubicin; prednisone; azacytidine

Weill Medical College of Cornell University - Recruiting 18 years or older.
- Phase I/II Trial of Azacytidine + R-CHOP in Diffuse Large B-Cell Lymphoma.
rituximab; cyclophosphamide; vincristine; doxorubicin; prednisone; azacytidine

Lymphoma Clinical Trial using bleomycin sulfate; filgrastim; rituximab; cyclophosphamide; cytarabine; doxorubicin hydrochloride; etoposide phosphate; ifosfamide; methotrexate; prednisolone; prednisone; vincristine sulfate; vindesine

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma (IELSG 26).
bleomycin sulfate; filgrastim; rituximab; cyclophosphamide; cytarabine; doxorubicin hydrochloride; etoposide phosphate; ifosfamide; methotrexate; prednisolone; prednisone; vincristine sulfate; vindesine

Non-Hodgkin's Lymphoma Clinical Trial using Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)

Grupo Espa¤ol de Linfomas y Transplante Aut¢logo de M‚dula Osea - Recruiting 18 years to 70 years.
- Autologous Transplantation of Haematopoietic Stem Cells With Conditioning Including Zevalin + BEAM to Patients Suffering From Refractory Large B-Cell Diffuse Lymphom.
Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)

Non-Hodgkin Lymphoma Clinical Trial using Rituximab

Instituto Nacional de Cancerologia de Mexico - Recruiting 15 years to 60 years.
- Selection of Young Patients (< 61 Years), With Good Prognosis Diffuse Large B Cell Lymphoma, According to the Immunophenotype (BCL-6 Negative) to be Treated With Chemoimmunotherapy, With R-CHOP. A Pilot Study..
Rituximab